Why the study?
The meta-analysis was conducted to compare the safety and efficacy of ARNI with ARBs and ACEi in patients with heart failure with reduced ejection fraction.
Does treatment with ARNI improve clinical outcomes and ejection fraction in patients with HFrEF compared to ACEi or ARBs?
Population
Patients with HFrEF across 10 included studies
Comparison
ARNI vs ARBs and ACEi
Design
Systematic review and meta-analysis
Authors
Loading...
ARNI lowers mortality versus ACEi/ARB in HFrEF; reinforces first-line use despite higher hypotension.
Does treatment with ARNI improve clinical outcomes and ejection fraction in patients with HFrEF compared to ACEi or ARBs?
ARNI therapy significantly reduces all-cause mortality and cardiovascular death in patients with HFrEF compared to ACEi/ARBs, supporting its use as first-line therapy despite an increased risk of hypotension.
Haseeb et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: